Evaluate the potential of ART combined with interferon therapy to achieve functional cure of hepatitis B in HIV/HBV co-infected patients
This is a prospective, non-randomized, clinical observational cohort study. The subjects are the advantageous population for functional cure of hepatitis B in HIV/HBV co-infected patients . Depending on whether interferon therapy is used in the real world , the patients are divided into two groups: the ART combined with interferon group and the ART alone group, with 30 cases in each group. Hepatitis B surface antigen seroclearance rate and seroconversion rate will be observed during the study period.
Study Type
OBSERVATIONAL
Enrollment
60
The pegylated interferon α-2b injection is administered subcutaneously at a dose of 180ug once a week.
Guangzhou Eighth People's Hospital, Guangzhou Medical University
Guangzhou, Guangdong, China
RECRUITINGHepatitis B surface antigen seroclearance
Hepatitis B surface antigen quantification less than 0.05 IU/mL.
Time frame: 48 weeks
Hepatitis B surface antigen seroconversion
Clearance of surface antigen concurrently accompanied by the production of surface antibodies
Time frame: 48 weeks
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.